	    		            		                                                                                                                                          	    		   		   	  	   	    							    	    																																			    																	    	    	                             		       	                                                                                                           	        						    	    																																			    																	    	    	                             		       	                                                                                                       									    	    																																			    																	    	    	                             		       	                                                                                                       									    	    																																			    																	    	    	                             		       	                                                                                                       	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                                                                                                                                                                                   	     <!DOCTYPE html><html><head>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - RIFAMPIN- rifampin capsule  </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "RIFAMPIN- rifampin capsule <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>    <script src="/dailymed/scripts/spin.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>            <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.min.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>					</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>																			<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>					</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">RIFAMPIN- rifampin capsule <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0ARIFAMPIN%2D%20Rifampin%20Capsule%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D55816042%2D946d%2D4bec%2D9461%2Dbd998628ff45%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=8db5bef1-33c2-4d65-a655-8f5546936b69-02.jpg&setid=55816042-946d-4bec-9461-bd998628ff45" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=8db5bef1-33c2-4d65-a655-8f5546936b69-02.jpg&setid=55816042-946d-4bec-9461-bd998628ff45" src="image.cfm?type=img&name=8db5bef1-33c2-4d65-a655-8f5546936b69-02.jpg&setid=55816042-946d-4bec-9461-bd998628ff45" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=8db5bef1-33c2-4d65-a655-8f5546936b69-03.jpg&setid=55816042-946d-4bec-9461-bd998628ff45" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="1">                                                 	<img id="zoom_2" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=8db5bef1-33c2-4d65-a655-8f5546936b69-03.jpg&setid=55816042-946d-4bec-9461-bd998628ff45" src="image.cfm?type=img&name=8db5bef1-33c2-4d65-a655-8f5546936b69-03.jpg&setid=55816042-946d-4bec-9461-bd998628ff45" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                </ul>                                    </li>                                </ul>								                                </div>            								                                                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                                                                                                    <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22RIFAMPIN%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=RIFAMPIN" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=RIFAMPIN" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=RIFAMPIN[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=RIFAMPIN/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=RIFAMPIN/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=RIFAMPIN/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=RIFAMPIN[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00207&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    0185-0799-01,                                                                                                                                        	                                    0185-0799-05,                                                                                                                                        	                                    0185-0799-30,                                                                                                                                        	                                    0185-0799-60,                                                                        	<a class="view-more show-js" href="#">view more</a><div class="more-codes"><span>                                                                                                                                        	                                    0185-0801-01,                                                                                                                                        	                                    0185-0801-05,                                                                                                                                        	                                    0185-0801-30                                                                                                                                                                        	</span>                                    </div>                                                                								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>Eon Labs, Inc.</li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                                   </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">Abbreviated New Drug Application</span></li>								                            </ul>							                                                                                            <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	02/14                                                                                                     </p>                                                                                                                                                     <p class="orangetext">If you are a consumer or patient please visit <a class="audience-context-switch consumer" href="dailymed/drugInfo.cfm?setid=55816042-946d-4bec-9461-bd998628ff45&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a download class="pdf" href="dailymed/getFile.cfm?setid=55816042-946d-4bec-9461-bd998628ff45&amp;type=pdf&amp;name=55816042-946d-4bec-9461-bd998628ff45" target="_blank">PDF</a>                                                    	<a download class="xml" href="dailymed/getFile.cfm?setid=55816042-946d-4bec-9461-bd998628ff45&amp;type=zip&amp;name=RIFAMPIN" target="_blank">XML</a>                                                    </li>                                                                                                                                                            <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=55816042-946d-4bec-9461-bd998628ff45&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li><a href="#">SPL UNCLASSIFIED SECTION</a> <div class="Section toggle-content closed" data-sectioncode="42229-5">   <a name="i4i_section_id_61bc3808-0422-438f-8361-9c5210108282"></a>  <a name="section-1"></a>   <p></p>   <p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of rifampin capsules USP and other antibacterial drugs, rifampin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="i4i_description_id_c94e1843-cd64-44f8-9f32-e40162896aee"></a>  <a name="section-2"></a>   <p></p>    <p class="First">Rifampin is a semisynthetic antibiotic derivative of rifamycin SV. Rifampin is a red-brown crystalline powder very slightly soluble in water at neutral pH, freely soluble in chloroform, soluble in ethyl acetate and in methanol. Its molecular weight is 822.95 and its chemical formula is C<span class="Sub">43</span>H<span class="Sub">58</span>N<span class="Sub">4</span>O<span class="Sub">12</span>. The chemical name for rifampin is either: 3-[[(4-Methyl-1-piperazinyl) imino]-methyl] rifamycin or 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino) naphtho [2,1-<span class="Italics">b</span>]furan-1,11(2H)-dione 21-acetate.</p>   <p>Its structural formula is:</p>   <div class="Figure">    <a name="id339"></a>   <img src="image.cfm?setid=55816042-946d-4bec-9461-bd998628ff45&name=8db5bef1%2D33c2%2D4d65%2Da655%2D8f5546936b69%2D01%2Ejpg" alt="chemical structure" />  </div>   <p>Rifampin capsules, for oral administration, contain 150 mg or 300 mg rifampin per capsule. In addition, the 150 mg and 300 mg capsules also contain the following inactive ingredients: colloidal silicon dioxide, corn starch, D&amp;C Yellow #10 aluminum lake, docusate sodium, FD&amp;C blue #1, FD&amp;C blue #1 aluminum lake, FD&amp;C blue #2 aluminum lake, FD&amp;C red #40, FD&amp;C red #40 aluminum lake, gelatin, magnesium stearate, microcrystalline cellulose, propylene glycol, shellac glaze, sodium benzoate, black iron oxide, talc, and titanium dioxide. The 150 mg capsules also contain D&amp;C yellow #10, and D&amp;C Red #28.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="i4i_clinical_pharmacology_id_d5584ba4-3ccb-4d5c-a8b9-829761d45a5b"></a>  <a name="section-3"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_8d29465a-3438-496c-beaf-55c0aa900f67"></a>   <a name="section-3.1"></a>    <p></p>    <h2>Oral Administration</h2>    <p class="First">Rifampin is readily absorbed from the gastrointestinal tract. Peak serum concentrations in healthy adults and pediatric populations vary widely from individual to individual. Following a single 600 mg oral dose of rifampin in healthy adults, the peak serum concentration averages 7 mcg/mL but may vary from 4 to 32 mcg/mL. Absorption of rifampin is reduced by about 30% when the drug is ingested with food.</p>    <p>Rifampin is widely distributed throughout the body. It is present in effective concentrations in many organs and body fluids, including cerebrospinal fluid. Rifampin is about 80% protein bound. Most of the unbound fraction is not ionized and, therefore, diffuses freely into tissues.</p>    <p>In healthy adults, the mean biological half-life of rifampin in serum averages 3.35 &plusmn; 0.66 hours after a 600 mg oral dose, with increases up to 5.08 &plusmn; 2.45 hours reported after a 900 mg dose. With repeated administration, the half-life decreases and reaches average values of approximately 2 to 3 hours. The half-life does not differ in patients with renal failure at doses not exceeding 600 mg daily, and consequently, no dosage adjustment is required. The half-life of rifampin at a dose of 720 mg daily has not been established in patients with renal failure. Following a single 900 mg oral dose of rifampin in patients with varying degrees of renal insufficiency, the mean half-life increased from 3.6 hours in healthy adults to 5, 7.3, and 11 hours in patients with glomerular filtration rates of 30 to 50 mL/min, less than 30 mL/min, and in anuric patients, respectively. Refer to the <span class="Bold"><a href="#i4i_warnings_id_cc12d0b6-2ffd-4d96-bd22-1a98c04c2c59">WARNINGS</a></span> section for information regarding patients with hepatic insufficiency.</p>    <p>After absorption, rifampin is rapidly eliminated in the bile, and an enterohepatic circulation ensues. During this process, rifampin undergoes progressive deacetylation so that nearly all the drug in the bile is in this form in about 6 hours. This metabolite has antibacterial activity. Intestinal reabsorption is reduced by deacetylation, and elimination is facilitated. Up to 30% of a dose is excreted in the urine, with about half of this being unchanged drug.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_598b571a-5b96-4084-98cc-c106dac8460a"></a>   <a name="section-3.2"></a>    <p></p>    <h2>Pediatrics</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="i4i_section_id_29a77778-486c-429e-8ea7-3afe25686886"></a>    <a name="section-3.2.1"></a>     <p></p>     <h3>Oral Administration </h3>     <p class="First">In one study, pediatric patients 6 to 58 months old were given rifampin suspended in simple syrup or as dry powder mixed with applesauce at a dose of 10 mg/kg body weight. Peak serum concentrations of 10.7 &plusmn; 3.7 and 11.5 &plusmn; 5.1 mcg/mL were obtained 1 hour after preprandial ingestion of the drug suspension and the applesauce mixture, respectively. After the administration of either preparation, the t<span class="Sub">1/2</span> of rifampin averaged 2.9 hours. It should be noted that in other studies in pediatric populations, at doses of 10 mg/kg body weight, mean peak serum concentrations of 3.5 mcg/mL to 15 mcg/mL have been reported.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_47769574-2f13-42a1-915d-966cc6bb49b4"></a>   <a name="section-3.3"></a>    <p></p>    <h2>Microbiology</h2>    <p class="First"> <span class="Bold"><span class="Italics">Mechanism of Action</span></span> </p>    <p>Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible <span class="Italics">Mycobacterium tuberculosis</span> organisms. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. </p>    <p> <span class="Bold"><span class="Italics">Drug Resistance</span></span> </p>    <p>Organisms resistant to rifampin are likely to be resistant to other rifamycins.</p>    <p> <span class="Bold">In the treatment of both tuberculosis and the meningococcal carrier state (see INDICATIONS AND USAGE), the small number of resistant cells present within large populations of susceptible cells can rapidly become predominant. In addition, resistance to rifampin has been determined to occur as single-step mutations of the DNA-dependent RNA polymerase. Since resistance can emerge rapidly, appropriate susceptibility tests should be performed in the event of persistent positive cultures.</span> </p>    <p> <span class="Bold"><span class="Italics">Activity in vitro and in vivo</span></span> </p>    <p>Rifampin has bactericidal activity <span class="Italics">in vitro</span> against slow and intermittently growing <span class="Italics">M tuberculosis</span> organisms.</p>    <p>Rifampin has been shown to be active against most strains of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical infections as described in the <span class="Bold"><a href="#i4i_indications_id_d9c185e1-81af-493f-80f1-dace02605528">INDICATIONS AND USAGE</a></span> section.</p>    <dl>     <dt>     &nbsp;    </dt>     <dd>     Aerobic Gram-Negative Microorganisms:    </dd>     <dt>     &nbsp;    </dt>     <dd>      <span class="Italics">Neisseria meningitidis</span>     </dd>     <dt>     &nbsp;    </dt>     <dd>     “Other” Microorganisms:    </dd>     <dt>     &nbsp;    </dt>     <dd>      <span class="Italics">Mycobacterium tuberculosis</span>     </dd>    </dl>    <p>The following <span class="Italics">in vitro </span>data are available, <span class="Underline">but their clinical significance is unknown</span>.</p>    <p>Rifampin exhibits <span class="Italics">in vitro </span>activity against most strains of the following microorganisms; however, the safety and effectiveness of rifampin in treating clinical infections due to these microorganisms have not been established in adequate and well controlled trials.</p>    <dl>     <dt>     &nbsp;    </dt>     <dd>     Aerobic Gram-Positive Microorganisms:    </dd>     <dt>     &nbsp;    </dt>     <dd>      <span class="Italics">Staphylococcus </span>     <span class="Italics">aureus</span>     <span class="Italics"></span>(including Methicillin-Resistant      <span class="Italics">S. </span>     <span class="Italics">aureus</span>/MRSA)    </dd>     <dt>     &nbsp;    </dt>     <dd>      <span class="Italics">Staphylococcus epidermis</span>     </dd>     <dt>     &nbsp;    </dt>     <dd>     Aerobic Gram-Negative Microorganisms:    </dd>     <dt>     &nbsp;    </dt>     <dd>      <span class="Italics">Haemophilus</span>     <span class="Italics"></span>     <span class="Italics">influenzae</span>     </dd>     <dt>     &nbsp;    </dt>     <dd>     “Other” Microorganisms:    </dd>     <dt>     &nbsp;    </dt>     <dd>      <span class="Italics">Mycobacterium </span>     <span class="Italics">leprae</span>     </dd>    </dl>    <p>&szlig;-lactamase production should have no effect on rifampin activity.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_208d9f7a-9b34-4b79-85eb-53e5ba308bd7"></a>   <a name="section-3.4"></a>    <p></p>    <h2>Susceptibility Testing</h2>    <p class="First">Prior to initiation of therapy, appropriate specimens should be collected for identification of the infecting organism and <span class="Italics">in vitro </span>susceptibility tests.</p>    <p> <span class="Italics">In vitro </span>testing for <span class="Italics">Mycobacterium tuberculosis </span>isolates:</p>    <p>Two standardized <span class="Italics">in vitro </span>susceptibility methods are available for testing rifampin against <span class="Italics">M tuberculosis</span> organisms. The agar proportion method (CDC or CLSI<span class="Sup">1</span> M24-A) utilizes Middlebrook 7H10 medium impregnated with rifampin at a final concentration of 1 mcg/mL to determine drug resistance. After three weeks of incubation MIC<span class="Sub">99</span> values are calculated by comparing the quantity of organisms growing in the medium containing drug to the control cultures. Mycobacterial growth in the presence of drug, of at least 1% of the growth in the control culture, indicates resistance.</p>    <p>The radiometric broth method employs the BACTEC 460 machine to compare the growth index from untreated control cultures to cultures grown in the presence of 2 mcg/mL of rifampin. Strict adherence to the manufacturer’s instructions for sample processing and data interpretation is required for this assay.</p>    <p>Susceptibility test results obtained by the two different methods can only be compared if the appropriate rifampin concentration is used for each test method as indicated above. Both procedures require the use of <span class="Italics">M tuberculosis </span>H37Rv ATCC 27294 as a control organism.</p>    <p>The clinical relevance of <span class="Italics">in vitro </span>susceptibility test results for mycobacterial species other than <span class="Italics">M tuberculosis</span> using either the radiometric or the proportion method has not been determined.</p>    <p> <span class="Italics">In vitro </span>testing for <span class="Italics">Neisseria </span><span class="Italics">meningitidis</span><span class="Italics"></span>isolates:</p>    <p>Dilution Techniques: Quantitative methods that are used to determine minimum inhibitory concentrations provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure uses a standardized dilution method<span class="Sup">2</span><span class="Sup">,4</span> (broth, agar, or microdilution) or equivalent with rifampin powder. The MIC values obtained should be interpreted according to the following criteria for <span class="Italics">Neisseria </span><span class="Italics">meningitidis</span><span class="Italics">.</span> </p>    <div class="scrollingtable">    <table>      <colgroup>      <col width="17%" />       <col width="21%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Toprule" valign="top"> <p class="First">MIC (mcg/mL)</p> </td>       <td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">Interpretation</p> </td>       </tr>       <tr>        <td class="Botrule Lrule" valign="top"> <p class="First">≤1</p> </td>       <td class="Botrule Lrule Rrule" valign="top"> <p class="First">(S) Susceptible</p> </td>       </tr>       <tr>        <td class="Botrule Lrule" valign="top"> <p class="First">2</p> </td>       <td class="Botrule Lrule Rrule" valign="top"> <p class="First">(I) Intermediate</p> </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule" valign="top"> <p class="First">≥4</p> </td>       <td class="Botrule Lrule Rrule" valign="top"> <p class="First">(R) Resistant</p> </td>       </tr>      </tbody>     </table>   </div>    <p>A report of “susceptible” indicates that the pathogen is likely to be inhibited by usually achievable concentrations of the antimicrobial compound in the blood. A report of “intermediate” indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where the maximum acceptable dose of drug can be used. This category also provides a buffer zone that prevents small-uncontrolled technical factors from causing major discrepancies in interpretation. A report of “resistant” indicates that usually achievable concentrations of the antimicrobial compound in the blood are unlikely to be inhibitory and that other therapy should be selected.</p>    <p>Measurement of MIC or minimum bactericidal concentrations (MBC) and achieved antimicrobial compound concentrations may be appropriate to guide therapy in some infections. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_d5584ba4-3ccb-4d5c-a8b9-829761d45a5b">CLINICAL PHARMACOLOGY</a></span> section for further information on drug concentrations achieved in infected body sites and other pharmacokinetic properties of this antimicrobial drug product.) </p>    <p>Standardized susceptibility test procedures require the use of laboratory control microorganisms. The use of these microorganisms does not imply clinical efficacy (see <span class="Bold"><a href="#i4i_indications_id_d9c185e1-81af-493f-80f1-dace02605528">INDICATIONS AND USAGE</a></span>); they are used to control the technical aspects of the laboratory procedures. Standard rifampin powder should give the following MIC values:</p>    <div class="scrollingtable">    <table>      <colgroup>      <col width="33%" />       <col width="33%" />       <col width="32%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Toprule" valign="top"> <p class="First">Microorganism</p> </td>       <td class="Botrule Lrule Toprule" valign="top"></td>       <td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">MIC (mcg/mL)</p> </td>       </tr>       <tr>        <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Italics">Staphylococcus </span><span class="Italics">aureus</span> </p> </td>       <td class="Botrule Lrule" valign="top"> <p class="First">ATCC 29213</p> </td>       <td class="Botrule Lrule Rrule" valign="top"> <p class="First">0.008 - 0.06</p> </td>       </tr>       <tr>        <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Italics">Enterococcus </span><span class="Italics">faecalis</span> </p> </td>       <td class="Botrule Lrule" valign="top"> <p class="First">ATCC 29212</p> </td>       <td class="Botrule Lrule Rrule" valign="top">         <dl>          <dt>          &nbsp;         </dt>          <dd>          1 - 4         </dd>         </dl> </td>       </tr>       <tr>        <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Italics">Escherichia coli</span> </p> </td>       <td class="Botrule Lrule" valign="top"> <p class="First">ATCC 25922</p> </td>       <td class="Botrule Lrule Rrule" valign="top"> <p class="First">8 - 32</p> </td>       </tr>       <tr>        <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Italics">Pseudomonas </span><span class="Italics">aeruginosa</span> </p> </td>       <td class="Botrule Lrule" valign="top"> <p class="First">ATCC 27853</p> </td>       <td class="Botrule Lrule Rrule" valign="top"> <p class="First">32 - 64</p> </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Italics">Haemophilus</span><span class="Italics"></span><span class="Italics">influenzae</span> </p> </td>       <td class="Botrule Lrule" valign="top"> <p class="First">ATCC 49247</p> </td>       <td class="Botrule Lrule Rrule" valign="top"> <p class="First">0.25 - 1</p> </td>       </tr>      </tbody>     </table>   </div>    <p>Diffusion Techniques: Quantitative methods that require measurement of zone diameters provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">3</span><span class="Sup">,4</span> that has been recommended for use with disks to test the susceptibility of microorganisms to rifampin uses the 5 mcg rifampin disk. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for rifampin.</p>    <p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg rifampin disk should be interpreted according to the following criteria for <span class="Italics">Neisseria meningitides</span>:</p>    <div class="scrollingtable">    <table>      <colgroup>      <col width="24%" />       <col width="27%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Toprule" valign="top"> <p class="First">Zone Diameter (mm)</p> </td>       <td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">Interpretation</p> </td>       </tr>       <tr>        <td class="Botrule Lrule" valign="top"> <p class="First">≥ 20</p> </td>       <td class="Botrule Lrule Rrule" valign="top"> <p class="First">(S) Susceptible </p> </td>       </tr>       <tr>        <td class="Botrule Lrule" valign="top"> <p class="First">17 - 19</p> </td>       <td class="Botrule Lrule Rrule" valign="top"> <p class="First">(I) Intermediate</p> </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule" valign="top"> <p class="First">≤ 16</p> </td>       <td class="Botrule Lrule Rrule" valign="top"> <p class="First">(R) Resistant</p> </td>       </tr>      </tbody>     </table>   </div>    <p>Interpretation should be as stated above for results using dilution techniques.</p>    <p>As with standard dilution techniques, diffusion methods require the use of laboratory control microorganisms. The use of these microorganisms does not imply clinical efficacy (see <span class="Bold"><a href="#i4i_indications_id_d9c185e1-81af-493f-80f1-dace02605528">INDICATIONS AND USAGE</a></span>); they are used to control the technical aspects of the laboratory procedures. The 5 mcg rifampin disk should provide the following zone diameters in these quality control strains:</p>    <div class="scrollingtable">    <table>      <colgroup>      <col width="26%" />       <col width="23%" />       <col width="24%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Toprule" valign="top"> <p class="First">Microorganism </p> </td>       <td class="Botrule Lrule Toprule" valign="top"></td>       <td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">Zone Diameter (mm)</p> </td>       </tr>       <tr>        <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Italics">S. </span><span class="Italics">aureus</span> </p> </td>       <td class="Botrule Lrule" valign="top"> <p class="First">ATCC 25923</p> </td>       <td class="Botrule Lrule Rrule" valign="top"> <p class="First">26 - 34</p> </td>       </tr>       <tr>        <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Italics">E. coli </span> </p> </td>       <td class="Botrule Lrule" valign="top"> <p class="First">ATCC 25922</p> </td>       <td class="Botrule Lrule Rrule" valign="top"> <p class="First">8 - 10</p> </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Italics">H. </span><span class="Italics">influenzae</span> </p> </td>       <td class="Botrule Lrule" valign="top"> <p class="First">ATCC 49247</p> </td>       <td class="Botrule Lrule Rrule" valign="top"> <p class="First">22 - 30</p> </td>       </tr>      </tbody>     </table>   </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="i4i_indications_id_d9c185e1-81af-493f-80f1-dace02605528"></a>  <a name="section-4"></a>   <p></p>    <p class="First">In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified.</p>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_02fa72fa-4f7f-4bf9-9188-5b122debe5a1"></a>   <a name="section-4.1"></a>    <p></p>    <h2>Tuberculosis</h2>    <p class="First">Rifampin is indicated in the treatment of all forms of tuberculosis.</p>    <p>A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER<span class="Sup">&reg;</span> (Sanofi-aventis U.S. LLC)) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin, and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. </p>    <p>Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE<span class="Sup">&reg;</span> (Sanofi-aventis U.S. LLC)) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.</p>    <p>Rifampin IV is indicated for the initial treatment and retreatment of tuberculosis when the drug cannot be taken by mouth.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_a16a75d3-17e0-47d1-aa10-a51022e622b4"></a>   <a name="section-4.2"></a>    <p></p>    <h2>Meningococcal Carriers</h2>    <p class="First">Rifampin is indicated for the treatment of asymptomatic carriers of <span class="Italics">Neisseria </span><span class="Italics">meningitidis</span><span class="Italics"></span>to eliminate meningococci from the nasopharynx. <span class="Bold">Rifampin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms. </span>(See <span class="Bold"><a href="#i4i_warnings_id_cc12d0b6-2ffd-4d96-bd22-1a98c04c2c59">WARNINGS</a></span>.)</p>    <p>Rifampin should not be used indiscriminately, and therefore, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed for establishment of the carrier state and the correct treatment. So that the usefulness of rifampin in the treatment of asymptomatic meningococcal carriers is preserved, the drug should be used only when the risk of meningococcal disease is high.</p>    <p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of rifampin and other antibacterial drugs, rifampin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="i4i_contraindications_id_8cbc63ec-4895-4046-a126-ef72d67688c5"></a>  <a name="section-5"></a>   <p></p>    <p class="First">Rifampin is contraindicated in patients with a history of hypersensitivity to rifampin or any of the components, or to any of the rifamycins. (See <span class="Bold"><a href="#i4i_warnings_id_cc12d0b6-2ffd-4d96-bd22-1a98c04c2c59">WARNINGS</a></span>.)</p>   <p>Rifampin is contraindicated in patients who are also receiving ritonavir-boosted saquinavir due to an increased risk of severe hepatocellular toxicity. (See <span class="Bold"><a href="#i4i_precautions_id_d789e9e2-3ad1-46af-938e-8a7bba9b061e">PRECAUTIONS</a>, <a href="#i4i_section_id_7fd74740-91c2-4e66-80a9-485e37e592c2">Drug Interactions</a></span>.) </p>   <p>Rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs, which may result in loss of antiviral efficacy and/or development of viral resistance. </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">WARNINGS</a> <div class="Section toggle-content closed" data-sectioncode="34071-1">   <a name="i4i_warnings_id_cc12d0b6-2ffd-4d96-bd22-1a98c04c2c59"></a>  <a name="section-6"></a>   <p></p>    <p class="First">Rifampin has been shown to produce liver dysfunction. Fatalities associated with jaundice have occurred in patients with liver disease and in patients taking rifampin with other hepatotoxic agents. Patients with impaired liver function should be given rifampin only in cases of necessity and then with caution and under strict medical supervision. In these patients, careful monitoring of liver function, especially SGPT/ALT and SGOT/AST should be carried out prior to therapy and then every 2 to 4 weeks during therapy. If signs of hepatocellular damage occur, rifampin should be withdrawn.</p>   <p>In some cases, hyperbilirubinemia resulting from competition between rifampin and bilirubin for excretory pathways of the liver at the cell level can occur in the early days of treatment. An isolated report showing a moderate rise in bilirubin and/or transaminase level is not in itself an indication for interrupting treatment; rather, the decision should be made after repeating the tests, noting trends in the levels, and considering them in conjunction with the patient’s clinical condition.</p>   <p>Rifampin has enzyme-inducing properties, including induction of delta amino levulinic acid synthetase. Isolated reports have associated porphyria exacerbation with rifampin administration.</p>   <p>The possibility of rapid emergence of resistant meningococci restricts the use of rifampin to short-term treatment of the asymptomatic carrier state. <span class="Bold">Rifampin is not to be used for the treatment of meningococcal disease.</span> </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="42232-9">   <a name="i4i_precautions_id_d789e9e2-3ad1-46af-938e-8a7bba9b061e"></a>  <a name="section-7"></a>   <p></p>    <div class="Section" data-sectioncode="34072-9">    <a name="i4i_precautions_general_id_e8f2d4c8-41eb-41c6-9b25-ca0e61dfbdd7"></a>   <a name="section-7.1"></a>    <p></p>    <h2>General</h2>    <p class="First">Rifampin should be used with caution in patients with a history of diabetes mellitus, as diabetes management may be more difficult.</p>    <p>Prescribing rifampin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>    <p>For the treatment of tuberculosis, rifampin is usually administered on a daily basis. Doses of rifampin greater than 600 mg given once or twice weekly have resulted in a higher incidence of adverse reactions, including the “flu syndrome” (fever, chills and malaise), hematopoietic reactions (leukopenia, thrombocytopenia, or acute hemolytic anemia), cutaneous, gastrointestinal, and hepatic reactions, shortness of breath, shock, anaphylaxis, and renal failure. Recent studies indicate that regimens using twice-weekly doses of rifampin 600 mg plus isoniazid 15 mg/kg are much better tolerated.</p>    <p>Rifampin is not recommended for intermittent therapy; the patient should be cautioned against intentional or accidental interruption of the daily dosage regimen since rare renal hypersensitivity reactions have been reported when therapy was resumed in such cases. </p>    <p>Rifampin has enzyme induction properties that can enhance the metabolism of endogenous substrates including adrenal hormones, thyroid hormones, and vitamin D. Rifampin and isoniazid have been reported to alter vitamin D metabolism. In some cases, reduced levels of circulating 25-hydroxy vitamin D and 1,25-dihydroxy vitamin D have been accompanied by reduced serum calcium and phosphate, and elevated parathyroid hormone.</p>   </div>   <div class="Section" data-sectioncode="34076-0">    <a name="i4i_info_patients_id_2863ee54-651e-4734-bcc4-71f91e34d593"></a>   <a name="section-7.2"></a>    <p></p>    <h2>Information for patients</h2>    <p class="First">Patients should be counseled that antibacterial drugs including rifampin should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When rifampin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by rifampin or other antibacterial drugs in the future.</p>    <p> <span class="Bold">The patient should be told that rifampin may produce a reddish coloration of the urine, sweat, sputum, and tears, and the patient should be forewarned of this.</span> Soft contact lenses may be permanently stained.</p>    <p>The patient should be advised that the reliability of oral or other systemic hormonal contraceptives may be affected; consideration should be given to using alternative contraceptive measures.</p>    <p>Patients should be instructed to take rifampin either 1 hour before or 2 hours after a meal with a full glass of water.</p>    <p>Patients should be instructed to notify their physicians promptly if they experience any of the following: fever, loss of appetite, malaise, nausea and vomiting, darkened urine, yellowish discoloration of the skin and eyes, and pain or swelling of the joints.</p>    <p>Compliance with the full course of therapy must be emphasized, and the importance of not missing any doses must be stressed.</p>   </div>   <div class="Section" data-sectioncode="34075-2">    <a name="i4i_lab_tests_id_aa29cf91-17f9-4bd9-8014-6171160e1ec4"></a>   <a name="section-7.3"></a>    <p></p>    <h2>Laboratory Tests</h2>    <p class="First">Adults treated for tuberculosis with rifampin should have baseline measurements of hepatic enzymes, bilirubin, serum creatinine, a complete blood count, and a platelet count (or estimate). Baseline tests are unnecessary in pediatric patients unless a complicating condition is known or clinically suspected.</p>    <p>Patients should be seen at least monthly during therapy and should be specifically questioned concerning symptoms associated with adverse reactions. All patients with abnormalities should have follow-up, including laboratory testing, if necessary. Routine laboratory monitoring for toxicity in people with normal baseline measurements is generally not necessary.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_7fd74740-91c2-4e66-80a9-485e37e592c2"></a>   <a name="section-7.4"></a>    <p></p>    <h2>Drug Interactions</h2>    <p class="First">Healthy subjects who received rifampin 600 mg once daily concomitantly with saquinavir 1000 mg/ritonavir 100 mg twice daily (ritonavir-boosted saquinavir) developed severe hepatocellular toxicity. Therefore, concomitant use of these medications is contraindicated. (See <span class="Bold"><a href="#i4i_contraindications_id_8cbc63ec-4895-4046-a126-ef72d67688c5">CONTRAINDICATIONS</a></span>.) </p>    <div class="Section" data-sectioncode="42229-5">     <a name="i4i_section_id_50fe21a6-8e42-46f4-81ec-2a9628331c99"></a>    <a name="section-7.4.1"></a>     <p></p>     <h3> <span class="Italics">Enzyme Induction</span> </h3>     <p class="First">Rifampin is known to induce certain cytochrome P-450 enzymes. Administration of rifampin with drugs that undergo biotransformation through these metabolic pathways may accelerate elimination of coadministered drugs. To maintain optimum therapeutic blood levels, dosages of drugs metabolized by these enzymes may require adjustment when starting or stopping concomitantly administered rifampin.</p>     <p>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See <span class="Bold"><a href="#i4i_contraindications_id_8cbc63ec-4895-4046-a126-ef72d67688c5">CONTRAINDICATIONS</a></span>.) </p>     <p>Rifampin has been reported to accelerate the metabolism of the following drugs: anticonvulsants (e.g., phenytoin), digitoxin, antiarrhythmics (e.g., disopyramide, mexiletine, quinidine, tocainide), oral anticoagulants, antifungals (e.g., fluconazole, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal contraceptives, dapsone, diazepam, doxycycline, fluoroquinolones (e.g., ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas) levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and zidovudine. It may be necessary to adjust the dosages of these drugs if they are given concurrently with rifampin.</p>     <p>Patients using oral or other systemic hormonal contraceptives should be advised to change to nonhormonal methods of birth control during rifampin therapy.</p>     <p>Rifampin has been observed to increase the requirements for anticoagulant drugs of the coumarin type. In patients receiving anticoagulants and rifampin concurrently, it is recommended that the prothrombin time be performed daily or as frequently as necessary to establish and maintain the required dose of anticoagulant.</p>     <p> <span class="Italics">Other Interactions</span> </p>     <p>When the two drugs were taken concomitantly, decreased concentrations of atovaquone and increased concentrations of rifampin were observed.</p>     <p>Concurrent use of ketoconazole and rifampin has resulted in decreased serum concentrations of both drugs. Concurrent use of rifampin and enalapril has resulted in decreased concentrations of enalaprilat, the active metabolite of enalapril. Dosage adjustments should be made if indicated by the patient’s clinical condition.</p>     <p>Concomitant antacid administration may reduce the absorption of rifampin. Daily doses of rifampin should be given at least 1 hour before the ingestion of antacids.</p>     <p>Probenecid and cotrimoxazole have been reported to increase the blood level of rifampin.</p>     <p>When rifampin is given concomitantly with either halothane or isoniazid, the potential for hepatotoxicity is increased. The concomitant use of rifampin and halothane should be avoided. Patients receiving both rifampin and isoniazid should be monitored closely for hepatotoxicity.</p>     <p>Plasma concentrations of sulfapyridine may be reduced following the concomitant administration of sulfasalazine and rifampin. This finding may be the result of alteration in the colonic bacteria responsible for the reduction of sulfasalazine to sulfapyridine and mesalamine.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_f95ae891-aa5d-4720-a2d2-a967ef2f5066"></a>   <a name="section-7.5"></a>    <p></p>    <h2>Drug/Laboratory Interactions</h2>    <p class="First">Cross-reactivity and false-positive urine screening tests for opiates have been reported in patients receiving rifampin when using the KIMS (Kinetic Interaction of Microparticles in Solution) method (e.g., Abuscreen OnLine opiates assay; Roche Diagnostic Systems). Confirmatory tests, such as gas chromatography/ mass spectrometry, will distinguish rifampin from opiates.</p>    <p>Therapeutic levels of rifampin have been shown to inhibit standard microbiological assays for serum folate and vitamin B<span class="Sub">12</span>. Thus, alternate assay methods should be considered. Transient abnormalities in liver function tests (e.g., elevation in serum bilirubin, alkaline phosphatase, and serum transaminases) and reduced biliary excretion of contrast media used for visualization of the gallbladder have also been observed. Therefore, these tests should be performed before the morning dose of rifampin.</p>   </div>   <div class="Section" data-sectioncode="34083-6">    <a name="i4i_carcinogenesis_mutagenesis_fertility_id_37817821-f93c-48e3-9a1b-85b2b6141ad4"></a>   <a name="section-7.6"></a>    <p></p>    <h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>    <p class="First">A few cases of accelerated growth of lung carcinoma have been reported in man, but a causal relationship with the drug has not been established. Hepatomas were increased in female (C3Hf/DP) mice dosed for 60 weeks with rifampicin followed by an observation period of 46 weeks, at 20 to 120 mg/kg (equivalent to 0.1 to 0.5 times the maximum dosage used clinically, based on body surface area comparisons). There was no evidence of tumorigenicity in male C3Hf/DP mice or in similar studies in BALB/c mice, or in two year studies in Wistar rats.</p>    <p>There was no evidence of mutagenicity in both prokaryotic (<span class="Italics">Salmonella </span><span class="Italics">typhi</span><span class="Italics">, Escherichia coli</span>) and eukaryotic (<span class="Italics">Saccharomyces </span><span class="Italics">cerevisiae</span>) bacteria, <span class="Italics">Drosophila melanogaster, </span>or ICR/Ha Swiss mice. An increase in chromatid breaks was noted when whole blood cell cultures were treated with rifampin. Increased frequency of chromosomal aberrations was observed <span class="Italics">in vitro </span>in lymphocytes obtained from patients treated with combinations of rifampin, isoniazid, and pyrazinamide and combinations of streptomycin, rifampin, isoniazid, and pyrazinamide.</p>   </div>   <div class="Section" data-sectioncode="42228-7">    <a name="i4i_pregnancy_id_6ec68ef4-9788-49a9-bc19-13f3fa5459e3"></a>   <a name="section-7.7"></a>    <p></p>    <h2>Pregnancy-Teratogenic Effects</h2>    <p class="First">Category C. Rifampin has been shown to be teratogenic in rodents. Congenital malformations, primarily spina bifida were increased in the offspring of pregnant rats given rifampin during organogenesis at oral doses of 150 to 250 mg/kg/day (about 1 to 2 times the maximum recommended human dose based on body surface area comparisons). Cleft palate was increased in a dose-dependent fashion in fetuses of pregnant mice treated at oral doses of 50 to 200 mg/kg (about 0.2 to 0.8 times the maximum recommended human dose based on body surface area comparisons). Imperfect osteogenesis and embryotoxicity were also reported in pregnant rabbits given rifampin at oral doses up to 200 mg/kg/day (about 3 times the maximum recommended human dose based on body surface area comparisons). There are no adequate and well-controlled studies of rifampin in pregnant women. Rifampin has been reported to cross the placental barrier and appear in cord blood. Rifampin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_c36044b4-6c17-4ef8-9f35-4162a8e458e8"></a>   <a name="section-7.8"></a>    <p></p>    <h2>Pregnancy-Non-Teratogenic Effects</h2>    <p class="First">When administered during the last few weeks of pregnancy, rifampin can cause post-natal hemorrhages in the mother and infant for which treatment with vitamin K may be indicated.</p>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="i4i_nursing_mothers_id_ef735526-2c42-4c02-a26a-5fa50d528f14"></a>   <a name="section-7.9"></a>    <p></p>    <h2>Nursing Mothers</h2>    <p class="First">Because of the potential for tumorigenicity shown for rifampin in animal studies, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="i4i_pediatric_use_id_10e418d9-61f5-4a6a-9577-f8b7e2f7804c"></a>   <a name="section-7.10"></a>    <p></p>    <h2>Pediatric Use</h2>    <p class="First">See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_d5584ba4-3ccb-4d5c-a8b9-829761d45a5b">CLINICAL PHARMACOLOGY</a> - <a href="#i4i_section_id_598b571a-5b96-4084-98cc-c106dac8460a">Pediatrics</a>; </span>see also <span class="Bold"><a href="#i4i_dosage_admin_id_7ddeb0a4-22e5-49cf-a572-e3edab079dbf">DOSAGE AND ADMINISTRATION</a></span>.</p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="i4i_geriatric_use_id_969afa23-382c-4ac7-800e-c21e671fb5e7"></a>   <a name="section-7.11"></a>    <p></p>    <h2>Geriatric Use</h2>    <p class="First">Clinical studies of rifampin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Caution should therefore be observed in using rifampin in elderly patients. (See <span class="Bold"><a href="#i4i_warnings_id_cc12d0b6-2ffd-4d96-bd22-1a98c04c2c59">WARNINGS</a></span>).</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="i4i_adverse_effects_id_3df3539c-e451-412a-8c5f-43689e267c5f"></a>  <a name="section-8"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_e65fcad5-ce23-4a56-8bf4-b7bb31211c39"></a>   <a name="section-8.1"></a>    <p></p>    <h2>Gastrointestinal</h2>    <p class="First">Heartburn, epigastric distress, anorexia, nausea, vomiting, jaundice, flatulence, cramps, and diarrhea have been noted in some patients. Although <span class="Italics">Clostridium </span><span class="Italics">difficile</span><span class="Italics"></span>has been shown <span class="Italics">in vitro </span>to be sensitive to rifampin, pseudomembranous colitis has been reported with the use of rifampin (and other broad spectrum antibiotics). Therefore, it is important to consider this diagnosis in patients who develop diarrhea in association with antibiotic use.</p>    <p> <span class="Bold">Hepatic</span> </p>    <p>Transient abnormalities in liver function tests (e.g., elevations in serum bilirubin, alkaline phosphatase, serum transaminases) have been observed. Rarely, hepatitis or a shock-like syndrome with hepatic involvement and abnormal liver function tests has been reported. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_c8e59eff-0fe9-46af-b51d-33807e232158"></a>   <a name="section-8.2"></a>    <p></p>    <h2>Hematologic</h2>    <p class="First">Thrombocytopenia has occurred primarily with high dose intermittent therapy, but has also been noted after resumption of interrupted treatment. It rarely occurs during well supervised daily therapy. This effect is reversible if the drug is discontinued as soon as purpura occurs. Cerebral hemorrhage and fatalities have been reported when rifampin administration has been continued or resumed after the appearance of purpura.</p>    <p>Rare reports of disseminated intravascular coagulation have been observed.</p>    <p>Leukopenia, hemolytic anemia, and decreased hemoglobin have been observed.</p>    <p>Agranulocytosis has been reported very rarely.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_f5fd7586-f89b-40a9-ab9a-071d21de5972"></a>   <a name="section-8.3"></a>    <p></p>    <h2>Central Nervous System</h2>    <p class="First">Headache, fever, drowsiness, fatigue, ataxia, dizziness, inability to concentrate, mental confusion, behavioral changes, muscular weakness, pains in extremities, and generalized numbness have been observed.</p>    <p>Psychoses have been rarely reported.</p>    <p>Rare reports of myopathy have also been observed. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_29757d0a-409a-4e04-8f20-a50661e71b79"></a>   <a name="section-8.4"></a>    <p></p>    <h2>Ocular</h2>    <p class="First">Visual disturbances have been observed.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_b206371d-c92a-4dcd-8586-f8454fec4665"></a>   <a name="section-8.5"></a>    <p></p>    <h2>Endocrine</h2>    <p class="First">Menstrual disturbances have been observed.</p>    <p>Rare reports of adrenal insufficiency in patients with compromised adrenal function have been observed.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_1c771bea-2238-4ab6-a7ad-f8aa7eb1a2e5"></a>   <a name="section-8.6"></a>    <p></p>    <h2>Renal</h2>    <p class="First">Elevations in BUN and serum uric acid have been reported. Rarely, hemolysis, hemoglobinuria, hematuria, interstitial nephritis, acute tubular necrosis, renal insufficiency, and acute renal failure have been noted. These are generally considered to be hypersensitivity reactions. They usually occur during intermittent therapy or when treatment is resumed following intentional or accidental interruption of a daily dosage regimen, and are reversible when rifampin is discontinued and appropriate therapy instituted.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_989071f9-ee3c-45f6-a7a0-30d78be1fc5e"></a>   <a name="section-8.7"></a>    <p></p>    <h2>Dermatologic</h2>    <p class="First">Cutaneous reactions are mild and self-limiting and do not appear to be hypersensitivity reactions.</p>    <p>Typically, they consist of flushing and itching with or without a rash. More serious cutaneous reactions which may be due to hypersensitivity occur but are uncommon.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_f53e73c4-770d-4848-aa96-b473c8121875"></a>   <a name="section-8.8"></a>    <p></p>    <h2>Hypersensitivity Reactions</h2>    <p class="First">Occasionally, pruritis, urticaria, rash, pemphigoid reaction, erythema multiforme including Stevens-Johnson Syndrome, toxic epidermal necrolysis, vasculitis, eosinophilia, sore mouth, sore tongue, and conjunctivitis have been observed.</p>    <p>Anaphylaxis has been reported rarely.</p>   </div>   <div class="Section" data-sectioncode="34085-1">    <a name="i4i_controlled_substance_id_0a31592e-38c3-4e60-879d-814e2a86f267"></a>   <a name="section-8.9"></a>    <p></p>    <h2>Miscellaneous </h2>    <p class="First">Edema of the face and extremities have been reported. Other reactions which have occurred with intermittent dosage regimens include “flu syndrome” (such as episodes of fever, chills, headache, dizziness, and bone pain), shortness of breath, wheezing, decrease in blood pressure and shock. The “flu syndrome” may also appear if rifampin is taken irregularly by the patient or if daily administration is resumed after a drug free interval.</p>    <p> <span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747</span> </p>    <p> <span class="Bold">or</span><span class="Bold"> FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="42229-5">   <a name="i4i_section_id_76d28b86-cb26-4de2-9e6c-c2c6f60d84c2"></a>  <a name="section-9"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_3c23a859-a807-4c46-8e65-3927b038c5cd"></a>   <a name="section-9.1"></a>    <p></p>    <h2>Signs and Symptoms</h2>    <p class="First">Nausea, vomiting, abdominal pain, pruritus, headache, and increasing lethargy will probably occur within a short time after ingestion; unconsciousness may occur when there is severe hepatic disease. Transient increases in liver enzymes and/or bilirubin may occur. Brownish-red or orange discoloration of the skin, urine, sweat, saliva, tears, and feces will occur, and its intensity is proportional to the amount ingested.</p>    <p>Liver enlargement, possibly with tenderness, can develop within a few hours after severe overdosage; bilirubin levels may increase and jaundice may develop rapidly. Hepatic involvement may be more marked in patients with prior impairment of hepatic function. Other physical findings remain essentially normal. A direct effect upon the hematopoietic system, electrolyte levels, or acid-base balance is unlikely. </p>    <p>Facial or periorbital edema has also been reported in pediatric patients. Hypotension, sinus tachycardia, ventricular arrhythmias, seizures and cardiac arrest were reported in some fatal cases.</p>   </div>   <div class="Section" data-sectioncode="34086-9">    <a name="i4i_abuse_id_620461bf-71a5-45dc-8df9-22cb7150c29b"></a>   <a name="section-9.2"></a>    <p></p>    <h2>Acute Toxicity</h2>    <p class="First">The minimum acute lethal or toxic dose is not well established. However, nonfatal acute overdoses in adults have been reported with doses ranging from 9 to 12 gm rifampin. Fatal acute overdoses in adults have been reported with doses ranging from 14 to 60 gm. Alcohol or a history of alcohol abuse was involved in some of the fatal and nonfatal reports. Nonfatal overdoses in pediatric patients ages 1 to 4 years old of 100 mg/kg for one to two doses has been reported.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_c3319e2a-c43d-4aed-b5ec-5a125f4361b5"></a>   <a name="section-9.3"></a>    <p></p>    <h2>Treatment</h2>    <p class="First">Intensive support measures should be instituted and individual symptoms treated as they arise. The airway should be secured and adequate respiratory exchange established. Since nausea and vomiting are likely to be present, gastric lavage within the first 2 to 3 hours after ingestion is probably preferable to induction of emesis. Following evacuation of the gastric contents, the instillation of activated charcoal slurry into the stomach may help absorb any remaining drug from the gastrointestinal tract. Antiemetic medication may be required to control severe nausea and vomiting. </p>    <p>Active diuresis (with measured intake and output) will help promote excretion of the drug. </p>    <p>For severe cases, extracorporeal hemodialysis may be required. If this is not available, peritoneal dialysis can be used along with forced diuresis. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="i4i_dosage_admin_id_7ddeb0a4-22e5-49cf-a572-e3edab079dbf"></a>  <a name="section-10"></a>   <p></p>    <p class="First">Rifampin can be administered by the oral route (see <span class="Bold"><a href="#i4i_indications_id_d9c185e1-81af-493f-80f1-dace02605528">INDICATIONS AND USAGE</a></span>). See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_d5584ba4-3ccb-4d5c-a8b9-829761d45a5b">CLINICAL PHARMACOLOGY</a></span> for dosing information in patients with renal failure.</p>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_c65db760-c90e-4e0b-8e22-d71e1c38de9c"></a>   <a name="section-10.1"></a>    <p></p>    <h2>Tuberculosis</h2>    <p class="First">Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, orally.</p>    <p>Pediatric Patients: 10 to 20 mg/kg, not to exceed 600 mg/day, orally.</p>    <p>It is recommended that oral rifampin capsule be administered once daily, either 1 hour before or 2 hours after a meal with a full glass of water.</p>    <p>Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide (e.g., RIFATER<span class="Sup">&reg;</span> (Sanofi-aventis U.S. LLC)) is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.</p>    <p>Following the initial phase, treatment should be continued with rifampin and isoniazid (e.g., RIFAMATE<span class="Sup">&reg;</span> (Sanofi-aventis U.S. LLC)) for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_619e5fcd-3849-4d39-9e09-7225b2c3cb75"></a>   <a name="section-10.2"></a>    <p></p>    <h2>Meningococcal Carriers</h2>    <p class="First">Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.</p>    <p>Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.</p>    <p>Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_a5abc2fc-fe1b-44a3-82c4-8b57a4201934"></a>   <a name="section-10.3"></a>    <p></p>    <h2>Preparation of Extemporaneous Oral Suspension</h2>    <p class="First">For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:</p>    <p>Rifampin 1% w/v suspension (10 mg/mL) can be compounded using one of four syrups-Simple Syrup (Syrup NF), Simple Syrup (Humco Laboratories), Syrpalta<span class="Sup">&reg;</span> Syrup (Emerson Laboratories) or Raspberry Syrup (Humco Laboratories).</p>    <dl>     <dt>     1.    </dt>     <dd>     Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper.    </dd>     <dt>     2.    </dt>     <dd>     If necessary, gently crush the capsule contents with a spatula to produce a fine powder.    </dd>     <dt>     3.    </dt>     <dd>     Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.    </dd>     <dt>     4.    </dt>     <dd>     Rinse the paper and spatula with 20 mL of one of the above mentioned syrups, and add the rinse to the bottle. Shake vigorously.    </dd>     <dt>     5.    </dt>     <dd>     Add 100 mL of syrup to the bottle and shake vigorously.    </dd>    </dl>    <p>This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 &plusmn; 3&deg; C) or in a refrigerator (2 to 8&deg; C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">HOW SUPPLIED</a> <div class="Section toggle-content closed" data-sectioncode="34069-5">   <a name="i4i_how_supplied_id_5c1e89d3-3f39-486f-833c-d3290c7c334c"></a>  <a name="section-11"></a>   <p></p>    <p class="First">Rifampin Capsules USP, 150 mg are orange capsules, imprinted <span class="Italics">E</span> 801 in black ink on both cap and body. They are available as follows:</p>   <p>NDC 0185-0801-30, bottles of 30 capsules</p>   <p>NDC 0185-0801-01, bottles of 100 capsules</p>   <p>NDC 0185-0801-05, bottles of 500 capsules</p>   <p>Rifampin Capsules USP, 300 mg are red capsules, imprinted <span class="Italics">E</span> 799 in black ink on both cap and body. They are available as follows:</p>   <p>NDC 0185-0799-30, bottles of 30 capsules</p>   <p>NDC 0185-0799-60, bottles of 60 capsules</p>   <p>NDC 0185-0799-01, bottles of 100 capsules</p>   <p>NDC 0185-0799-05, bottles of 500 capsules</p>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_d6938cca-4afc-43b7-b857-315089fd3db2"></a>   <a name="section-11.1"></a>    <p></p>    <h2>Storage:</h2>    <p class="First">Store at 20&ordm; to 25&ordm; C (68&ordm; to 77&ordm; F) [See USP Controlled Room Temperature] <span class="Bold">Keep tightly closed.</span> . <span class="Bold">Store in a dry place.</span><span class="Bold"> Avoid excessive heat.</span> </p>    <p>Dispense contents with a child resistant closure (as required) and in a tight light-resistant container as defined in the USP/NF.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="i4i_section_id_c94c3e06-7e38-46ef-b022-7f83f7f93300"></a>   <a name="section-11.2"></a>    <p></p>    <h2>References:</h2>    <dl>     <dt>     1.    </dt>     <dd>     Clinical Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard CLSI Document M24-A, Vol. 23, No. 18, CLSI, Villanova, PA, 2003.     </dd>     <dt>     2.    </dt>     <dd>     Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically -- Eighth Edition. Approved Standard CLSI Document M7-A8, Vol. 29, No. 2, CLSI, Villanova, PA, January 2009.     </dd>     <dt>     3.    </dt>     <dd>     Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests -- Tenth Edition. Approved Standard CLSI Document M2-A10, Vol. 29, No. 41, CLSI, Villanova, PA, January 2009.     </dd>     <dt>     4.    </dt>     <dd>     Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement, CLSI Document M100-S20, Vol. 30, No. 1, CLSI, Villanova, PA, January 2010.     </dd>    </dl>    <p class="First"> <span class="Bold">Rx only</span> </p>    <p>Manufactured for Sandoz Inc. </p>    <p>Princeton, NJ 08540</p>    <p>Manufactured by Epic Pharma, LLC</p>    <p>Laurelton, NY 11413</p>    <p>Rev.09/2013</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="i4i_Principal_display_panel_id_ed4ef291-25d6-461b-9dfa-0fde84e9d074"></a>  <a name="section-12"></a>   <p></p>    <p class="First"> <span class="Bold">NDC</span> 0185-0801-01</p>   <p> <span class="Bold">Rifampin Capsules, USP</span> </p>   <p> <span class="Bold">150 mg</span> </p>   <p> <span class="Bold">Rx Only</span> </p>   <p> <span class="Bold">100 Capsules</span> </p>   <div class="Figure">    <a name="id799"></a>   <img src="image.cfm?setid=55816042-946d-4bec-9461-bd998628ff45&name=8db5bef1%2D33c2%2D4d65%2Da655%2D8f5546936b69%2D02%2Ejpg" alt="150 mg label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="i4i_section_id_98454e97-8cf5-45e3-9c1f-c973c700c4d9"></a>  <a name="section-13"></a>   <p></p>    <p class="First"> <span class="Bold">NDC</span> 0185-0799-30</p>   <p> <span class="Bold">Rifampin Capsules, USP</span> </p>   <p> <span class="Bold">300 mg</span> </p>   <p> <span class="Bold">Rx Only</span> </p>   <p> <span class="Bold">30 Capsules</span> </p>   <div class="Figure">    <a name="id808"></a>   <img src="image.cfm?setid=55816042-946d-4bec-9461-bd998628ff45&name=8db5bef1%2D33c2%2D4d65%2Da655%2D8f5546936b69%2D03%2Ejpg" alt="300 mg label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>RIFAMPIN&nbsp; </strong> <br /> <span class="contentTableReg">rifampin capsule</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0185-0801</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>RIFAMPIN</strong> (UNII: VJT6J7R4TR) (RIFAMPIN - UNII:VJT6J7R4TR)</td>          <td class="formItem">RIFAMPIN</td>          <td class="formItem">150&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>SILICON DIOXIDE</strong> (UNII: ETJ7Z6XBU4)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>STARCH, CORN</strong> (UNII: O8232NY3SJ)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong> (UNII: 35SW5USQ3G)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>DOCUSATE SODIUM</strong> (UNII: F05Q2T2JA0)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong> (UNII: H3R47K3TBD)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong> (UNII: L06K8R7DQK)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FD&amp;C RED NO. 40</strong> (UNII: WZB9127XOA)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>GELATIN</strong> (UNII: 2G86QN327L)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>SODIUM BENZOATE</strong> (UNII: OJ245FE5EU)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>PROPYLENE GLYCOL</strong> (UNII: 6DC9Q167V3)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERROSOFERRIC OXIDE</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>TALC</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>SHELLAC</strong> (UNII: 46N107B71O)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>D&amp;C RED NO. 28</strong> (UNII: 767IP0Y5NH)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">ORANGE (Medium orange opaque body and cap)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">CAPSULE</td>          <td class="formLabel">Size</td>          <td class="formItem">18mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">E801</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0185-0801-05</td>          <td class="formItem">500 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0185-0801-01</td>          <td class="formItem">100 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem">NDC:0185-0801-30</td>          <td class="formItem">30 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">ANDA</td>          <td class="formItem">ANDA064150</td>          <td class="formItem">01/02/1998</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>RIFAMPIN&nbsp; </strong> <br /> <span class="contentTableReg">rifampin capsule</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0185-0799</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>RIFAMPIN</strong> (UNII: VJT6J7R4TR) (RIFAMPIN - UNII:VJT6J7R4TR)</td>          <td class="formItem">RIFAMPIN</td>          <td class="formItem">300&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>SILICON DIOXIDE</strong> (UNII: ETJ7Z6XBU4)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>STARCH, CORN</strong> (UNII: O8232NY3SJ)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>DOCUSATE SODIUM</strong> (UNII: F05Q2T2JA0)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong> (UNII: H3R47K3TBD)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong> (UNII: L06K8R7DQK)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FD&amp;C RED NO. 40</strong> (UNII: WZB9127XOA)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>GELATIN</strong> (UNII: 2G86QN327L)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>SODIUM BENZOATE</strong> (UNII: OJ245FE5EU)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>PROPYLENE GLYCOL</strong> (UNII: 6DC9Q167V3)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FERROSOFERRIC OXIDE</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>TALC</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>SHELLAC</strong> (UNII: 46N107B71O)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong> (UNII: 35SW5USQ3G)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">RED (Swedish orange opaque body and cap)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">CAPSULE</td>          <td class="formLabel">Size</td>          <td class="formItem">18mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">E799</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0185-0799-05</td>          <td class="formItem">500 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:0185-0799-01</td>          <td class="formItem">100 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem">NDC:0185-0799-30</td>          <td class="formItem">30 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">4</th>          <td class="formItem">NDC:0185-0799-60</td>          <td class="formItem">60 in 1 BOTTLE</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">ANDA</td>          <td class="formItem">ANDA064150</td>          <td class="formItem">05/28/1997</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Eon Labs, Inc. (012656273) </td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                                                                                    <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22RIFAMPIN%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=RIFAMPIN" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=RIFAMPIN" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00207&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                                   <h3 class="long-title">RIFAMPIN- rifampin capsule <br></h3>            <h4>Number of versions: 5</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>Mar 18, 2014</td>                        <td>							                                6                             							(current)                         </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=133832">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Apr 16, 2013</td>                        <td>							                                5                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=105305">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Aug 7, 2012</td>                        <td>							                                4                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=84876">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jul 27, 2011</td>                        <td>							                                3                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=59970">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Nov 17, 2010</td>                        <td>							                                2                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=42780">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">RIFAMPIN- rifampin capsule <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                                       			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                                                    <tr class="psn-rxtty">                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=198201">198201</a></td>                              <td>rifampin 150 MG Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=198201">198201</a></td>                              <td>Rifampin 150 MG Oral Capsule</td>                        <td>SCD</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>3</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=198202">198202</a></td>                              <td>rifampin 300 MG Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>4</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=198202">198202</a></td>                              <td>Rifampin 300 MG Oral Capsule</td>                        <td>SCD</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">RIFAMPIN- rifampin capsule <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=55816042-946d-4bec-9461-bd998628ff45" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=55816042-946d-4bec-9461-bd998628ff45</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                    <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>            <li><a href="dailymed/help.cfm">Help</a></li>                    </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0ARIFAMPIN%2D%20Rifampin%20Capsule%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D55816042%2D946d%2D4bec%2D9461%2Dbd998628ff45%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><script> var ignore_onbeforeunload = false; $("a").on('click',function(){    if(ignore_onbeforeunload){        ignore_onbeforeunload = false;    }})$("a[href^='mailto'], a[href$='zip']").on('click',function(){    ignore_onbeforeunload = true;});$(window).on('beforeunload', function(){    if (!ignore_onbeforeunload){        // Only run the loading icon if changing the page takes longer than 200ms        setTimeout(function(){            // Fade in the grey screen            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"></div>').fadeIn('fast'));            var opts = {                  lines: 12 // The number of lines to draw                , length: 14 // The length of each line                , width: 5 // The line thickness                , radius: 14 // The radius of the inner circle                , scale: 1 // Scales overall size of the spinner                , corners: 1 // Corner roundness (0..1)                , color: '#fff'                 , opacity: 0.25 // Opacity of the lines                , rotate: 0 // The rotation offset                , direction: 1 // 1: clockwise, -1: counterclockwise                , speed: 1 // Rounds per second                , trail: 60 // Afterglow percentage                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS                , zIndex: 2e9 // The z-index (defaults to 2000000000)                , className: 'spinner' // The CSS class to assign to the spinner                , top: '50%' // Top position relative to parent                , left: '50%' // Left position relative to parent                , shadow: false // Whether to render a shadow                , hwaccel: false // Whether to use hardware acceleration                , position: 'absolute' // Element positioning                }            var spinner = new Spinner(opts).spin();            $('.loading-wrapper').append(spinner.el);        }, 200);    }    //ignore_onbeforeunload = false;});</script><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    